Navigation Links
Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Date:9/25/2007

treatment with standard medical care alone, with 1:1 randomization between the two groups. An adaptive design feature, increasingly common in FDA product approval trials, would permit the size of the trial to be increased after enrollment of the first 80 patients if the primary efficacy endpoint has not yet reached statistical significance but has shown a positive trend. A further and final potential extension of the trial would also be permitted to achieve statistical significance of one or more secondary endpoints of the trial relating to clinical, functional, and reimbursement advantages for SEPET(TM)-treated patients.

In parallel with the US-oriented pivotal clinical trial of the SEPET(TM) Liver Assist Device, Arbios intends to advance the product toward European market approval under the CE Mark. Arbios believes that such registration of SEPET(TM) could be accomplished significantly earlier than registration in the US, because a randomized, controlled trial is customarily not required under the European Medical Device Directives. Arbios plans to involve several leading European medical centers in the pivotal trial, so that the results of the trial will be relevant to both US and European patients and may be used to support medical payor (both private sector and government) coverage in both regions.

About Arbios' SEPET(TM) Liver Assist Device

The SEPET(TM) Liver Assist Device is a sterile, disposable cartridge containing microporous hollow fibers with proprietary permeability characteristics. When a patient's blood is passed through these fibers, blood plasma components of specific molecular weights are expressed through the micropores, thereby cleansing the blood of harmful impurities (e.g., hepatic failure toxins as well as various mediators of inflammation and inhibitors of liver regeneration). These substances would otherwise progressively accumulate in the patient's bloodstream during liver failure, causing hypotension, increasing risk of
'/>"/>

SOURCE Arbios Systems, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NEW YORK , Nov. 26, 2014 /PRNewswire/ ... is growing at a rate of 4%, with ... according to Kalorama Information. MRI and other types ... the diagnosis and treatment of numerous medical conditions ... different technologies and techniques. Kalorama,s report, Medical ...
(Date:11/26/2014)... 25, 2014 According to ... Power Source (Electric, Battery, Pneumatic), by Product (Drill, ... Cart), by Application (Orthopedic, ENT, Oral, Thoracic, Neurology) ... global Powered Surgical Instruments Market is estimated to ... 2014 and is expected to grow at a ...
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the leading ... recognized as a winner of Red Herring,s Top ... Top 100 North America award in 2013, marking its ... landscape. Red Herring,s Top 100 Global list ... new companies and entrepreneurs. Red Herring editors were among ...
Breaking Medicine Technology:Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3
... TransTech Medical Solutions is pleased to announce the expansion ... Center.  The new agreement increases the suite of services ... transcription and voice recognition editing services across a variety ... medical transcription and editing services provided by TransTech can ...
... 14, 2010 Samplify Systems, Inc., a leading ... ultrasound market, is pleased to announce that its ... won Electronic Design Magazine,s Best Electronic ...  Details of Samplify,s AutoFocus™ beamforming technology currently appear ...
Cached Medicine Technology:TransTech Medical Solutions Expands Offering to MD Anderson Cancer Center to Include Outsourced Medical Transcription and Editing Services 2Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2
(Date:11/28/2014)... 2014 A newly released article ... of the influenza virus that will soon be spreading across ... The article begins with a brief explanation of what the ... reminds families that children under the age of 5, adults ... diseases, such as heart and lung diseases, asthma, or diabetes, ...
(Date:11/28/2014)... 28, 2014 Patten Pecans, based in ... With those passions driving them, they've added a pecan ... tried other pecans oils, they've found this pecan ... be exceptionally flavorful, retaining the buttery pecan notes that ... nutritional benefits found in pecans nuts is found ...
(Date:11/28/2014)... 28, 2014 Schools like Centra ... providing quality commercial playground equipment to its students. ... to supply an affordable play structure at its ... , Centra provides comprehensive programs for children who ... support services. They have served the needs ...
(Date:11/28/2014)... talklocal ( http://www.talklocal.com ) is ... service professionals by phone in about 90 seconds. , ... tornadoes were reported to have touched down just north of ... following the tornadoes, Denver residents now know all too well ... is like having local pros in over 50 service categories ...
(Date:11/28/2014)... 2014 Nipomo Family Dentistry , ... recently opened its doors at 195 N. Thompson St., ... preventative care like teeth cleanings, oral exams, fillings, implants ... teeth whitening (and Kor whitening), laser whitening, gum tissue ... Family Dentistry’s five-person team also takes a philanthropic approach ...
Breaking Medicine News(10 mins):Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 2Health News:Centra Rivermont (VA) Provides School Playground Equipment from APCPLAY© for Special Needs Students 3Health News:TalkLocal Launches In Denver A Week After Multiple Tornadoes Hit Near City 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 2Health News:Nipomo Family Dentistry Opens New Dental Office in Nipomo 3
... Nov. 6 The following was released today,by ... recent report from the U.S. Department of Veterans ... substantiated waste,mismanagement and inaction to disclosures of fraud, ... Texas Veterans Health,Care System (CTVHCS)., Inaction to ...
... ) today reported results for the third quarter ended September,30, ... or $0.11 per,share, for the third quarter 2008 compared to ... the third quarter 2007. Cash and cash equivalents,totaled $6.1 million ... for the third quarter 2008 is due primarily to,a 26% ...
... vitality unclear, scientists say , , THURSDAY, Nov. 6 (HealthDay ... amounts of muscle-linked growth hormone in seniors to youthful ... therapy also gained muscle mass over the two-year trial, ... led to significant improvements in their strength or function. ...
... Conference Call Scheduled for Today - Thursday, November 6, 2008 at ... ... Calif., Nov. 6 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported ... 30, 2008, and provided an,update on its product development candidates. The ...
... MASI ), the inventor of Pulse CO-Oximetry(TM) and ... its,management is scheduled to present at the Lazard Capital ... York in New York, NY on,Wednesday, November 19, 2008, ... will be available on the Masimo website at, http://www.masimo.com ...
... RANCHO CORDOVA, Calif., Nov. 6 ThermoGenesis,Corp. (Nasdaq: ... that process and store adult stem cells, today reported ... for the quarter ended September 30, 2008, were $4.5 ... in the first quarter a,year ago. Disposable revenues were ...
Cached Medicine News:Health News:War Veterans With Traumatic Brain Injury Pay the Price of Waste at the VA, Says Dr. Robert Van Boven 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 3Health News:Pharmos Corporation Reports 2008 Third Quarter Results 4Health News:Pharmos Corporation Reports 2008 Third Quarter Results 5Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 2Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 3Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 4Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 5Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 6Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 7Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 8Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 9Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 10Health News:Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference 2Health News:ThermoGenesis Reports First Quarter 2009 Results 2Health News:ThermoGenesis Reports First Quarter 2009 Results 3Health News:ThermoGenesis Reports First Quarter 2009 Results 4Health News:ThermoGenesis Reports First Quarter 2009 Results 5Health News:ThermoGenesis Reports First Quarter 2009 Results 6Health News:ThermoGenesis Reports First Quarter 2009 Results 7Health News:ThermoGenesis Reports First Quarter 2009 Results 8
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... fit for all astigmatic patients. Ideal ... who require excellent visual acuity and ... of disposable lenses; astigmatic spectacle wearers ... lenses; and spherically masked astigmatic patients ...
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... device that delivers ganciclovir intraocularly in ... This approach can significantly delay progression ... intravenous treatment. The Vitrasert implant contains ... that slowly releases the drug. The ...
Medicine Products: